
MAGL-IN-4
CAS No. 2135785-20-3
MAGL-IN-4( His121 ARG57 )
Catalog No. M28832 CAS No. 2135785-20-3
MAGL-IN-4 is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 356 | Get Quote |
![]() ![]() |
10MG | 530 | Get Quote |
![]() ![]() |
25MG | 851 | Get Quote |
![]() ![]() |
50MG | 1152 | Get Quote |
![]() ![]() |
100MG | 1557 | Get Quote |
![]() ![]() |
500MG | 3114 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMAGL-IN-4
-
NoteResearch use only, not for human use.
-
Brief DescriptionMAGL-IN-4 is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.
-
DescriptionMAGL-IN-4 is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.(In Vitro):MAGL-IN-4 showed potent in vitro MAGL inhibitory activity (IC50 6.2 nM), good oral absorption and blood-brain barrier penetration.(In Vivo):MAGL-IN-4 showed significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3-10 mg/kg, po. in mice.
-
In VitroMAGL-IN-4 (compound 4f) shows a high LLE (5.9), a logD of 2.3 for MAGL.MAGL-IN-4 exhibits no inhibition toward the closely related serine hydrolases (FAAH and ABHD6; all IC50>10000 nM). MAGL-IN-4 has no significant binding potentials to cannabinoid receptors (CB1: 19% and CB2: 5% at 10 μM), and low hERG liability (14.4% inh. at 10 μM, manual patch clamp, without BSA).
-
In VivoMAGL-IN-4 (compound 4f; 0.1-10 mg/kg; oral; single dose) results in a significant elevation in the level of 2-AG and reduction in that of arachidonic acid (AA) from 0.3 mg/kg in C57BL/6J mice.
-
SynonymsHis121 ARG57
-
PathwayMetabolic Enzyme/Protease
-
TargetLipase
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2135785-20-3
-
Formula Weight364.82
-
Molecular FormulaC18H21ClN2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (274.11 mM)
-
SMILESO=C(OC1)N[C@@]21C[C@@H](C(N3CC(OCC4=CC=C(C)C(Cl)=C4)C3)=O)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jatczak, K., et al. Preparation of selectively protected protoescigenin derivatives for synthesis of escin analogs and neoglycoconjugates. cent.eur.j.chem. 12, 1222–1231 (2014).
molnova catalog



related products
-
Lalistat 2
Lalistat 2 is a selective inhibitor of lysosomal acid lipase with IC50 of 152 nM and exhibits no inhibition of human pancreatic lipase or bovine milk lipoprotein lipase (up to 10 μM).
-
JW 642
JW 642 is an effective inhibitor of monoacylglycerol lipase (MAGL)
-
NF-1819
NF-1819 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor.